© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Bone Biologics Corporation (BBLG) stock remained unchanged at $1.27 a share on NASDAQ. The stock opened at $1.27, fluctuating between $1.27 to $1.29 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 15, 2026 | 1.27 | 1.29 | 1.27 | 1.27 | 12.28K |
| May 14, 2026 | 1.28 | 1.35 | 1.27 | 1.27 | 13.48K |
| May 13, 2026 | 1.34 | 1.34 | 1.30 | 1.30 | 3.06K |
| May 12, 2026 | 1.28 | 1.31 | 1.28 | 1.31 | 7.07K |
| May 11, 2026 | 1.30 | 1.36 | 1.26 | 1.28 | 6.65K |
| May 08, 2026 | 1.29 | 1.34 | 1.29 | 1.32 | 7.87K |
| May 07, 2026 | 1.37 | 1.37 | 1.29 | 1.29 | 14.33K |
| May 06, 2026 | 1.35 | 1.40 | 1.33 | 1.33 | 18.3K |
| May 05, 2026 | 1.29 | 1.37 | 1.29 | 1.32 | 8.18K |
| May 04, 2026 | 1.38 | 1.38 | 1.34 | 1.34 | 3.73K |
| Apr 30, 2026 | 1.31 | 1.31 | 1.29 | 1.29 | 3.84K |
| Apr 29, 2026 | 1.32 | 1.32 | 1.29 | 1.31 | 4.28K |
| Apr 28, 2026 | 1.34 | 1.34 | 1.32 | 1.32 | 2.27K |
| Apr 27, 2026 | 1.37 | 1.40 | 1.36 | 1.38 | 8.07K |
| Apr 23, 2026 | 1.38 | 1.38 | 1.35 | 1.35 | 14.5K |
| Apr 22, 2026 | 1.40 | 1.43 | 1.38 | 1.41 | 13.47K |
| Apr 21, 2026 | 1.39 | 1.40 | 1.38 | 1.40 | 4.27K |
| Apr 20, 2026 | 1.35 | 1.40 | 1.35 | 1.38 | 8.7K |
| Apr 17, 2026 | 1.32 | 1.40 | 1.31 | 1.39 | 23.44K |
| Apr 16, 2026 | 1.31 | 1.33 | 1.30 | 1.32 | 7.9K |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Employees | 2 |
| Beta | 0.42 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |